S-CARBOXYMETHYLCYSTEINE IN FLUIDIFICATION OF SPUTUM AND TREATMENT OF CHRONIC AIRWAY-OBSTRUCTION
S-CARBOXYMETHYLCYSTEINE IN FLUIDIFICATION OF SPUTUM AND TREATMENT OF CHRONIC AIRWAY-OBSTRUCTION
复制标题
DOI：
10.1378/chest.70.4.506
复制
发表时间：
1976-01-01
期刊：
影响因子：
9.6
通讯作者：
JORDAN, JW
中科院分区：
文献类型：
--
作者：
EDWARDS, GF;STEEL, AE;JORDAN, JW
在短期住院试验和随后的长期门诊调查(3个月)中发现的临床结果和痰的变化。本文报道了一种新型粘液剂S-羧甲基半胱氨酸(粘液)治疗慢性支气管炎82例的双盲对照研究。在两个试验中，都观察到了痰的流态化，晨痰粘度的某些测量结果降低，伴随着咳出支气管分泌物的能力的改善，痰容量的显著增加，以及通风的改善(根据1 S的用力呼气量估计)，作为剂量相关反应，咳嗽的易感性增加，咳嗽频率和呼吸困难减少。S-羧甲基半胱氨酸治疗耐受性良好，没有立即或延迟的严重不良反应。该药在流态化痰中的作用可能是由于一种黏膜调节机制，该机制逆转了慢性支气管炎患者的痰大分子紊乱。
The clinical results and changes in sputum found in both a short-term inpatient trial and a subsequent long-term outpatient investigation (3 mo. double-blind controlled study) of 82 patients with chronic bronchitis treated with a new mucolytic agent, S-carboxymethylcysteine (Mucodyne), are reported. Fluidification of sputum with reduction in certain measurements of the viscosity of morning sputum aliquots, associated with improvement in the ability to cough up bronchial secretions, significant increase in sputum volume output, and improvement in ventilation (as estimated by the forced expiratory volume in 1 s), were observed in both trials as dose-related responses, with an increase in the ease of expectoration and a reduction in cough frequency and dyspnea. Therapy with S-carboxymethylcysteine was well tolerated, and there were no serious adverse effects, either immediate or delayed. The effect of the drug in fluidifying sputum may be due to a mucoregulatory mechanism which reverses the sputum macromolecular disturbances seen in chronic bronchitis.